title: B7-1 and interleukin 12 synergistically induce effective antitumor immunity.
abstract: Enhanced host rejection of tumor cells is the primary goal of cancer immunotherapy and, in many murine tumor models, has been accomplished by engineering cells to express B7 costimulatory molecules or creating an environment rich in certain cytokines. We examined the effect of tumor cell B7-1 expression and administered recombinant interleukin 12 (IL-12) on the syngeneic host response to rapidly growing, poorly immunogenic SCK mammary carcinoma cells and to more slowly growing, immunogenic K1735 melanoma cells. Whereas B7-1 expression induced rejection of K1735 cells in 78% of mice, and IL-12 induced rejection in 38%, B7-1 expression induced rejection of SCK cells in only 28% of mice, and IL-12 induced rejection in none. The relative ineffectiveness of either B7-1 or IL-12 alone to induce rejection of SCK cells led us to combine the two manipulations. This resulted in rejection of SCK cells in 74% of mice and dramatically delayed tumor development in the remainder. Tumor rechallenge studies indicated that the surviving mice developed specific immunity to wild-type SCK cells. Lymphocyte subset ablation and IFN-gamma depletion studies indicated that rejection of SCK tumor cells brought about by the synergistic effects of B7-1 and IL-12 is mediated by a rapidly developing, systemic antitumor immune response that is dependent on the presence of both CD8+ and CD4+ T cells and involves IFN-gamma. Additionally, the synergistic effect of B7-1 expression and IL-12 administration is capable of inducing rejection of control SCK tumors simultaneously established in the opposite flank. The efficacy of B7-1 and IL-12 in inducing protective immunity against a poorly immunogenic, aggressive murine tumor indicates that this combination is particularly effective at producing a potent antitumor immune response that may be of therapeutic benefit.
authors.affiliation: Biomedical Graduate Program, University of Pennsylvania, Philadelphia 19104, USA.
authors.forename: C M
authors.initials: CM
authors.lastname: Coughlin
authors.forename: M
authors.initials: M
authors.lastname: Wysocka
authors.forename: H L
authors.initials: HL
authors.lastname: Kurzawa
authors.forename: W M
authors.initials: WM
authors.lastname: Lee
authors.forename: G
authors.initials: G
authors.lastname: Trinchieri
authors.forename: S L
authors.initials: SL
authors.lastname: Eck
mesh_terms: D000818:Animals; D018122:B7-1 Antigen / Q000627:therapeutic use*; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D004357:Drug Synergism; D005260:Female; D006084:Graft Rejection / Q000276:immunology; D007113:Immunity, Innate; D007167:Immunotherapy; D007371:Interferon-gamma / Q000096:biosynthesis; D018664:Interleukin-12 / Q000627:therapeutic use*; D008325:Mammary Neoplasms, Experimental / Q000276:immunology* / Q000517:prevention & control* / Q000628:therapy; D008546:Melanoma, Experimental / Q000276:immunology* / Q000517:prevention & control*; D051379:Mice; D008805:Mice, Inbred A; D008809:Mice, Inbred C3H; D009368:Neoplasm Transplantation / Q000276:immunology*; D012680:Sensitivity and Specificity
chemical_list: D018122:B7-1 Antigen; D018664:Interleukin-12; D007371:Interferon-gamma